Heron Therapeutics (HRTX) Equity Average (2016 - 2025)
Historic Equity Average for Heron Therapeutics (HRTX) over the last 13 years, with Q3 2025 value amounting to -$6.2 million.
- Heron Therapeutics' Equity Average rose 8412.6% to -$6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.2 million, marking a year-over-year increase of 8412.6%. This contributed to the annual value of -$33.8 million for FY2024, which is 23147.39% down from last year.
- According to the latest figures from Q3 2025, Heron Therapeutics' Equity Average is -$6.2 million, which was up 8412.6% from -$27.9 million recorded in Q2 2025.
- In the past 5 years, Heron Therapeutics' Equity Average registered a high of $216.4 million during Q1 2021, and its lowest value of -$39.0 million during Q3 2024.
- Moreover, its 5-year median value for Equity Average was -$6.2 million (2025), whereas its average is $21.2 million.
- Per our database at Business Quant, Heron Therapeutics' Equity Average crashed by 949355.74% in 2023 and then skyrocketed by 8412.6% in 2025.
- Over the past 5 years, Heron Therapeutics' Equity Average (Quarter) stood at $98.2 million in 2021, then plummeted by 81.66% to $18.0 million in 2022, then plummeted by 271.45% to -$30.9 million in 2023, then decreased by 19.26% to -$36.8 million in 2024, then skyrocketed by 83.2% to -$6.2 million in 2025.
- Its Equity Average was -$6.2 million in Q3 2025, compared to -$27.9 million in Q2 2025 and -$31.1 million in Q1 2025.